KURA ONCOLOGY, INC. (NASDAQ:KURA) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

KURA ONCOLOGY, INC. (NASDAQ:KURA) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.

As reported below in Item 5.07, on June 9, 2017, the stockholders
of Kura Oncology, Inc. (the Company) approved an amendment to the
Companys Amended and Restated Certificate of Incorporation, as
amended, effective as of June 9, 2017, to, among other things,
implement a classified Board of Directors (the Board).The
amendment was filed with the Secretary of State of the State of
Delaware on June 9, 2017.

On June 9, 2017, the Board also approved the Companys Amended and
Restated Bylaws, to, among other things, implement a classified
Board.

The foregoing description does not purpose to be complete and is
qualified in its entirety by reference to the full text of the
Companys Amended and Restated Certificate of Incorporation, as
amended, and to the Companys Amended and Restated Bylaws, copies
of which are filed as Exhibits 3.1 and 3.2 to this current report
on Form 8-K and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Stockholders on June 9,
2017 (the Annual Meeting). As of the close of business on April
11, 2017, the record date for the Annual Meeting, there were
21,385,817 shares of common stock outstanding, of which
19,299,452 shares of common stock were present in person or
represented by proxy at the Annual Meeting. The final voting
results were as follows:

The Proposal to Approve an Amendment to the Companys Amended and
Restated Certificate of Incorporation, as amended

The amendment to the Companys Amended and Restated Certificate of
Incorporation, as amended, was approved by the following vote:

The Proposal Regarding the Election of Directors

The Companys stockholders elected the two persons listed below as
Class I directors, each to hold office until the Companys 2018
Annual Meeting of Stockholders and until their respective
successors are duly elected and qualified, or until their earlier
death, resignation or removal. The final voting results were as
follows:

The Companys stockholders elected the two persons listed below as
Class II directors, each to hold office until the Companys 2019
Annual Meeting of Stockholders and until their respective
successors are duly elected and qualified, or until their earlier
death, resignation or removal. The final voting results were as
follows:

The Companys stockholders elected the person listed below as a
Class III director to hold office until the Companys 2020 Annual
Meeting of Stockholders and until his successor is duly elected
and qualified, or until his earlier death, resignation or
removal. The final voting results were as follows:

The Proposal to Ratify the Selection of Independent Registered
Public Accounting Firm

The Companys stockholders ratified the selection of Ernst Young
LLP by the Audit Committee of the Board as the Companys
independent registered public accounting firm for the fiscal year
ending December 31, 2017. The final voting results were as
follows:

Item 7.01 Regulation FD Disclosure.

Beginning on June 14, 2017, members of the management team of the
Company will be providing presentation materials (the
Presentation) to certain interested parties.A copy of the
Presentation is attached hereto as Exhibit 99.1 and incorporated
herein by reference.

The information contained in this Current Report on Form 8-K
under Item 7.01 and Exhibit 99.1 hereto are being furnished and
shall not be deemed to be filed for the purposes of Section 18 of
the Securities and Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section and will not be
incorporated by reference into any registration statement filed
by the Company, under the Securities Act of 1933, as amended,
unless specifically identified as being incorporated therein by
reference. This Current Report on Form 8-K will not be deemed an
admission as to the materiality of any information in this
Current Report on Form 8-K that is being disclosed to Regulation
FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

About KURA ONCOLOGY, INC. (NASDAQ:KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.